Growth properties of optimal transition perturbations

Journal of the Atmospheric Sciences | August 1, 1999| | Copyright

ABSTRACT

The development of perturbations that optimally trigger the onset of Euro-Atlantic blocking (BL) and strong zonal flow (SZF) regimes has been investigated. These perturbations will be called optimal transition perturbations. First, a T21 three-level quasigeostrophic model (T21QG) including a forward and adjoint tangent propagator, is used to compute the sensitivity in the initial conditions for onset of BL and SZF regimes. The evolution of an optimal transition perturbation during a sensitive 72-h period is extensively studied. Barotropic and baroclinic mechanisms are distinguished ...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and trade journal articles from HighBeam Research

(Including press releases, facts, information, and biographies)

Callisto Pharmaceuticals Announces $5.14 Million Private Placement Financing of Common Stock and Warrants; Proceeds to Fund Acceleration of Clinical Trials of Drug Candidates and Expansion of Key Strategic Initiatives.
Business Wire ; NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL...financing will be used to continue to fund Callisto's strategic initiatives, including...clinical development activities. Callisto currently has two anticancer drug candidates...
Callisto CEO Video Spotlights Company's Drug Candidates to Treat Devastating Multiple Myeloma and Leukemia Blood Cancers; Drugs under Development as New Therapies for Patients Who Fail to Respond to Existing Treatments.
Business Wire ; NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL...video, CEO Dr. Gary S. Jacob outlines Callisto's drug development programs and describes...developed to fill this treatment void. "Callisto has assembled a world-class team of...
Callisto Announces First Berlin Issues Research Update Following Company's Announcement of New Data on Cancer Drug Efficacy; Independent German Based Equity Research Firm Maintains Buy Rating and Share Price Target of $2.50.
Business Wire ; NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL...issued the research update following Callisto's announcement that researchers in...the liver and gastrointestinal tract. Callisto is also developing Atiprimod as a therapy...
Callisto Announces Availability of Presentation Outlining Drug Development Pipeline and Market Opportunities; Development Programs Include New Drugs to Treat Leukemia and Multiple Myeloma Cancers, and to Fight Biowarfare Threats.
Business Wire ; NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL...drug to treat forms of leukemia. "Callisto is developing drugs such as Atiprimod...said Dr. Gary S. Jacob, CEO of Callisto. "There are significant numbers of...
Callisto Announces Report Update from Equity Analyst General Research with Projected Share Price of $3.00 and Buy Rating; Analyst Cites Recent Callisto Announcement of Encouraging Anti-Tumor Response of Drug Candidate Atiprimod.
Business Wire ; NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL...ago. The new target in part reflects Callisto's recent announcement of clinical...Research issued the update following Callisto's announcement that researchers in...
Callisto Names Veteran Investment Banker and Biotech Specialist Dan D'Agostino to Key Technology and Business Growth Role; D'Agostino to Direct M&A and Efforts to Expand Callisto Pipeline of New Drug Technologies and Candidates.
Business Wire ; NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL...portfolio. Mr. D'Agostino brings Callisto approximately 15 years' experience...sector will be an invaluable asset to Callisto as we continue to execute our business...
Callisto Announces Appointment of Dr. Arthur Sytkowski as Clinical Trial Advisor and Medical Safety Monitor; Veteran Scientist and Harvard Professor to Guide Callisto's Expanding Clinical Programs for Atiprimod and L-Annamycin.
Business Wire ; NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL...University, has agreed to serve as Callisto's Clinical Trial Advisor and Medical...Monitor. Dr. Sytkowski will advise on Callisto's expanding clinical programs to develop...
Callisto Announces Report Update from Equity Analyst General Research with Projected Share Price of US$3.00 and Buy Rating.
PR Newswire Europe ; ...PRNewswire/ -- - Analyst Cites Recent Callisto Announcement of Encouraging Anti...Response of Drug Candidate Atiprimod Callisto Pharmaceuticals, Inc. (Amex...The new target in part reflects Callisto's recent announcement of clinical...
Callisto Issues Updated Investor Fact Sheet to Reflect Recent Clinical Progress of Cancer Drug Candidate Atiprimod; Drug's Clear Response Against Carcinoid Tumors and Newly Planned Clinical Development Direction Noted in Fact Sheet.
Business Wire ; NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL...drug candidates. E[acute accent]Callisto recently announced plans to launch an...carcinoid patients. E[acute accent]The Callisto Investor Fact Sheet provides a succinct...
Callisto Announces Report Update from Equity Analyst General Research with Projected Share Price of $3.00 and Buy Rating.
PR Newswire ; Analyst Cites Recent Callisto Announcement of Encouraging Anti...March 14 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL...ago. The new target in part reflects Callisto's recent announcement of clinical...

Find more facts and information related to the article "Growth properties of optimal transition ..."